Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dilanubicel in Cord Blood Transplant for Hematologic Malignancies
NCT01175785Phase 2Completed
- Sponsor
- Nohla Therapeutics
- Start
- Aug 2010
- Primary completion
- Aug 2014
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Hematopoietic Stem Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dilanubicel in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML) and 1 more, sponsored by Nohla Therapeutics. Primary endpoints: Time to neutrophil engraftment at Day 42, Time to platelet engraftment at Day 100 and 6 more. Started Aug 2010; status: completed.
02
Drugs
dilanubicel
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myelogenous leukemia (CML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01175785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01175785.